GlassScriptPhysician profile
Vineet Bansal
NPI 1104068667
$1,417.72
in general payments reported to CMS, 2019-2025
22 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $64.14 · 2021: $67.27 · 2022: $289 · 2023: $241 · 2024: $18.69 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $193.05 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $189.44 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $162.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Genzyme Corporation | $110.00 | 2019 | |
| Lilly USA, LLC | $109.92 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.06 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $93.55 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $75.39 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $39.70 | 2025 | |
| Abbvie INC. | $38.29 | 2019-2025 | |
| Abbott Laboratories | $37.10 | 2022-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $35.91 | 2019-2025 | Veozah |
| Philips North America LLC | $31.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.73 | 2019 | |
| Pfizer INC. | $26.37 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $25.86 | 2019-2020 | |
| Dexcom, INC. | $25.75 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $24.72 | 2019-2022 | |
| Advanced Respiratory, INC | $22.16 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.47 | 2020 | |
| Exact Sciences Corporation | $16.89 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.